Bristol-Myers to file for OTC sale of its Pravachol statin

12/13/2004 | Wall Street Journal, The

Bristol-Myers Squibb has taken official action to get FDA approval to sell its cholesterol-lowering Pravachol over the counter, possibly paving the way for OTC versions of other statins. Bristol-Myers faces the loss of its patent on Pravachol in just over a year and OTC sales are seen as opening a new market for the drugs. An FDA advisory panel plans to meet in mid-January on a similar request by Merck for Mevacor.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX